Key takeaways
- Testosterone raises red cell production two ways at once: it increases erythropoietin and it suppresses hepcidin, freeing up iron for haemoglobin synthesis.
- Complete blood count at baseline, at three months, then at regular intervals.
- Testosterone stimulates red blood cell production through two mechanisms working in the same direction, which is why the effect is so consistent.
- Haematocrit is the percentage of your blood volume made up of red cells.
- The reason this problem is manageable is that it is visible on a cheap, routine test long before it causes anything.
Of everything that can go wrong on testosterone therapy, this is the one that actually does. Not the heart-attack fear that dominated the conversation for a decade, and not the things people ask about in forums — the red blood cell count. It rises in most men on treatment, it is completely invisible until it is not, and it is the single reason a complete blood count belongs on every follow-up panel.
Why it happens
Testosterone stimulates red blood cell production through two mechanisms working in the same direction, which is why the effect is so consistent.
The first is erythropoietin. Testosterone raises EPO, the kidney hormone that tells bone marrow to produce red cells, and it also appears to reset the relationship between EPO and haemoglobin — so the body settles at a higher red cell mass rather than correcting back to where it started.
The second is hepcidin. Hepcidin is the hormone that restricts iron availability; testosterone suppresses it, which frees up more iron for haemoglobin synthesis. More instruction to produce, more raw material to produce with (testosterone, EPO and hepcidin, J Gerontol A 2014).
This is not a side effect in the sense of something going wrong. It is the hormone doing what it does. It becomes a clinical problem only at the top end.
The two numbers, and what they mean
Haematocrit is the percentage of your blood volume made up of red cells. Haemoglobin is the oxygen-carrying protein inside them. They move together, and haematocrit is the one usually tracked because it is the one that describes the practical problem: how thick the blood is.
Above the reference range, blood viscosity rises. Higher viscosity means the heart works harder to move it, flow through small vessels slows, and clotting risk increases. That is the mechanism by which this matters, and it is why the concern is about the trajectory as much as any single reading.
Who is more likely to run into it
The rise is near-universal; the problem is not. What tips it over:
- Injectable delivery, particularly with large, infrequent doses. The peak matters, not just the average — which is one of the arguments for smaller, more frequent administration. See subcutaneous vs intramuscular.
- Untreated sleep apnoea. Repeated nocturnal oxygen desaturation is itself a stimulus for red cell production. Combine it with testosterone and the two effects stack. See testosterone and sleep architecture.
- Smoking, for the same reason — chronic carbon monoxide exposure raises baseline red cell mass.
- Altitude. Living high does the same thing, physiologically and legitimately.
- Dehydration, which does not raise red cell mass at all but raises the measured haematocrit, because the denominator shrank. This is the most common cause of a one-off alarming result.
- A high baseline before starting — men who begin near the top of the range have less room.
Before you act on a single high reading: check the conditions it was drawn under. A sample taken dehydrated, after a sauna, after hard training, or in the trough-to-peak window after an injection can read meaningfully higher than the same man's true steady state. Re-draw properly hydrated at a consistent point in the cycle before changing anything.
How it is managed
This is a well-understood problem with a well-understood ladder of responses, and it is a physician's decision at every rung. What that ladder looks like:
- Confirm it is real — proper hydration, consistent timing, repeat draw.
- Treat what else is driving it — apnoea is the big one, and treating it often resolves the problem without touching the protocol.
- Change the delivery pattern. Smaller, more frequent administration lowers the peak, and the peak is a large part of the stimulus.
- Reduce the dose. The relationship is dose-dependent, and a slightly lower level that is sustainable beats a higher one that is not.
- Therapeutic phlebotomy — donating or removing blood — where it is clinically indicated. Effective and straightforward, but it depletes iron over time, so it is monitored rather than used indefinitely as a workaround for a protocol that needs changing.
- Hydration and, if relevant, stopping smoking, both of which help and neither of which is sufficient alone.
The order matters. Phlebotomy used as a permanent substitute for adjusting the protocol treats the number rather than the cause, and it costs iron every time.
The monitoring schedule
The reason this problem is manageable is that it is visible on a cheap, routine test long before it causes anything. That is only true if the test is actually run.
- Complete blood count at baseline, before starting — you need to know where you began
- Again at around three months, when the trajectory becomes readable
- Again at six to twelve months, then at a regular interval
- Ferritin alongside it, especially if phlebotomy is being used
- Consistent conditions — same hydration state, same point in the injection cycle, so you are comparing like with like
Watch the direction, not just the value. A man climbing steadily inside the reference range is on a different trajectory from one sitting stably near the top, and the first is the one to intervene on early. Hematocrit management on TRT goes through this in more detail.
Where this sits among the real risks
It is worth putting this next to the risk that dominated the conversation for years. A large randomised trial in men with low testosterone and elevated cardiovascular risk found no increase in cardiovascular death, heart attack or stroke — see testosterone and cardiovascular outcomes. The fear that constrained treatment for a decade did not survive contact with randomised data.
Erythrocytosis did. It is the common one, the one that shows up on ordinary follow-up, and the one that a well-run protocol is actively watching for. Which is a reasonable trade: a monitorable, manageable, visible problem rather than an invisible one.
Bottom line
Testosterone raises red cell production through EPO and by suppressing hepcidin, so haematocrit rises in most men on treatment. It only becomes a problem at the top of the range, where blood viscosity starts to matter — and it is amplified by untreated sleep apnoea, smoking, altitude, large infrequent doses and simple dehydration. Confirm a high reading before acting on it, treat what else is driving it, adjust the delivery pattern or the dose, and use phlebotomy as a clinical tool rather than a permanent workaround. Get a complete blood count at baseline, at three months, and at regular intervals after that. This is the one that actually happens, and it is entirely manageable when somebody is looking.
Educational content, not medical advice. Laboratory interpretation and any treatment decision are made by a licensed physician after individual evaluation. Individual results vary.
